Zydus Cadila Begins Human Clinical Trials Of Covid-19 Vaccine Candidate
A French National Centre for Scientific Research researcher holds up a test tube containing cells to be infected with Covid-19 during coronavirus vaccine research work inside the Pasteur Institute laboratories in Lille, France. (Photographer: Adrienne Surprenant/Bloomberg)

Zydus Cadila Begins Human Clinical Trials Of Covid-19 Vaccine Candidate


Drug firm Zydus Cadila on Wednesday said it has started human clinical trials of its Covid-19 vaccine candidate ZyCoV-D.

In this phase of trials, the company will enroll over 1,000 subjects across multiple clinical study sites in India, it said in a regulatory filing.

The adaptive phase I/II human clinical trials of ZyCoV-D have commenced with the first human dosing, it said, adding that the adaptive phase I/II dose-escalation, multi-centric study will assess the safety, tolerability and immunogenicity of the vaccine.

Earlier this month, Zydus had received approval from domestic authorities to start human trials for its Covid-19 vaccine contender -- the second Indian pharmaceutical firm to get such nod amid a surge in novel coronavirus infections worldwide.

The approval came through a few days after India's first indigenous Covid-19 vaccine candidate Covaxin, developed by Bharat Biotech in collaboration with Indian Council of Medical Research and National Institute of Virology, got approval for human clinical trials from the Drug Controller General of India.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.